Joseph Scheeren, a global regulatory-affairs leader, began his new role as president and CEO of Tucson-based Critical Path Institute in April.
Scheeren, who has worked for more than three decades in the
pharmaceutical industry in the United States, China and Europe, including top
leadership roles in global regulatory affairs for Bayer AG, will lead the
nonprofit organization that functions as a third party in drug development and
the regulatory process for medical products as well as large-scale data sharing.
“C-Path and its partners define the type of innovation and solutions that health care needs now and into the future to provide patients hope and access to new treatments and cures by accelerating innovation in the development and approval pathway,” Scheeren said in a C-Path press release.
Scheeren serves on a number of international advisory boards and is a lecturer at Yale University and adjunct professor at Peking University in China. He holds a Pharm.D. from the University of Leiden in the Netherlands.
Former president and CEO Martha Brumfield, who is retiring, had led the organization since 2013. She will assist with the leadership transition as a special advisor to Scheeren for six months, according to the press release.
More than 1,5000 scientists from government and regulatory agencies, academia, patient organizations, disease foundations, and dozens of pharmaceutical and biotech companies work in consortia established by C-Path in Alzheimer’s, Parkinson’s, kidney disease, tuberculosis and other areas.
C-Path was founded in 2005 in partnership with the University of Arizona and the U.S. Food and Drug Administration to accelerate the pace and reduce the costs of medical product development through the creation of new data standards, measurement standards, and methods standards that aid in the scientific evaluation of the efficacy and safety of new therapies, according to the organization.
C-Path Selects Global Regulatory Affairs Leader as New President and CEO, Critical Path Institute